This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Deerfield, IL, Baxter International Inc. (BAX) is a global medical technology company. However, the company spun off its biopharmaceuticals segment into an independent entity – Baxalta Inc. Following the spinoff, the company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions.
US-North Korea Summit Talks Resume: 4 MedTech Stocks to Watch
by Nabaparna Bhattacharya
Here we take a look at four leading MedTech players that are gaining from opportunities in the APAC market
Baxter International (BAX) Hits a 52-Week High, Can the Run Continue?
by Zacks Equity Research
Baxter International Inc. is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for BAX for clues.
Baxter International (BAX) Up 3.5% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Baxter International (BAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medtronic (MDT) Q4 Earnings Beat on Growth in All Lines
by Zacks Equity Research
All major business groups of Medtronic (MDT) contribute to solid top-line growth at CER, which highlighted sustainability across groups and regions.
BioScrip's Core Business Strong Despite Reimbursement Issues
by Zacks Equity Research
BioScrip (BIOS) consistently advances with its multi-faceted CORE plan to perk up the money matters. However, reimbursement cuts pertaining to 21st century Cures Act might hinder growth in 2018.
Zacks.com highlights: Schweitzer-Mauduit International, Insight Enterprises, Baxter International, Fortinet and Comfort Systems USA
by Zacks Equity Research
Zacks.com highlights: Schweitzer-Mauduit International, Insight Enterprises, Baxter International, Fortinet and Comfort Systems USA
Baxter (BAX) Gets FDA Nod for Spectrum IQ, Secures Infusions
by Zacks Equity Research
Baxter (BAX) streamlines EMR integration for patients through FDA's approval of Spectrum IQ.
GNC Holdings' Global Prospects Solid, Competition Stiff
by Zacks Equity Research
GNC Holdings (GNC) progresses with deals to boost international presence.
CryoLife (CRY) Stock Gains 9.5% on Impressive Q1 Earnings
by Zacks Equity Research
CryoLife's (CRY) shares gain on growth in all product lines along with strong performance in all geographies in Q1.
Surmodics (SRDX) Hits a 52-Week High, Can the Run Continue?
by Zacks Equity Research
Surmodics, Inc. is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for SRDX for clues.
Orthofix (OFIX) Stock Declines 13% on '18 Earnings View Cut
by Zacks Equity Research
Despite the bottom line of Orthofix (OFIX) betters estimates, the company's shares drop due to trimmed 2018 earnings outlook.
5 Stocks Near 52-Week High With Scope to Perform Better
by Zacks Equity Research
Here are some stocks trading near their 52-week high levels and still have plenty of upside left.
Chemed (CHE) Stock is Worth a Bet Right Now: Here's Why
by Zacks Equity Research
Chemed (CHE) sees a stellar Q1 backed by steady year-over-year revenue growth in both of its subsidiaries.
BioScrip (BIOS) Q1 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
BioScrip's (BIOS) shift in strategy to raise core revenue mix hampers growth in Q1. Year-over-year rise in core product mix buoys optimism.
Zacks.com featured highlights include: Marine Products, Nutrisystem, Exelixis, Illumina and Baxter
by Zacks Equity Research
Zacks.com featured highlights include: Marine Products, Nutrisystem, Exelixis, Illumina and Baxter
Hospital Product Sales Drive Mallinckrodt (MNK) Q1 Earnings
by Ekta Bagri
Mallinckrodt's earnings and sales beat in the first quarter boosted investor sentiment as hospital products sales revived.
STERIS (STE) Q4 Earnings & Revenues Beat Estimates, Up Y/Y
by Zacks Equity Research
Favorable underlying market trends along with a slew of new product and service offerings by STERIS (STE) instill confidence in investors.
Wright Medical (WMGI) Beats on Q1 Earnings, Keeps Guidance
by Zacks Equity Research
Wright Medical's (WMGI) Q1 results solid; growth in upper and lower extremities segments encourages.
5 Winning Stocks With Superb Efficiency Level
by Tirthankar Chakraborty
A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance.
Haemonetics (HAE) Q4 Earnings Meet, Revenues Beat Estimates
by Zacks Equity Research
Continued generation of new business and geographical expansion drive Haemonetics' (HAE) Q4 results.
Penumbra (PEN) Q1 Earnings & Revenues Top Estimates, View Up
by Zacks Equity Research
Penumbra (PEN) benefits from strong growth across all geographies and product lines in Q1.
Luminex (LMNX) Beats Q1 Estimates on ARIES Platform Strength
by Zacks Equity Research
Luminex (LMNX) gains on ARIES and VERIGENE platforms in Q1; a solid guidance encourages.
Myriad Genetics (MYGN) Beats on Earnings & Revenues in Q3
by Zacks Equity Research
Myriad Genetics' (MYGN) Q3 revenues decline year over year. Strong demand for GeneSight, Vectra DA and Prolaris tests was encouraging.
Henry Schein's (HSIC) Q1 Earnings Beat, '18 View Intact
by Zacks Equity Research
We currently await the completion of Henry Schein's (HSIC) planned spin-off of global Animal Health business. This business contributes nearly 30% to the company's top line.
Amedisys (AMED) Q1 Earnings, Revenues Beat on Overall Growth
by Zacks Equity Research
Robust growth in Medicare and non-Medicare revenues at Amedisys' (AMED) Home Health and Hospice divisions boost the company's Q1 results.